Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 319-323

  Ding, Xiu Ping ^a   Zhang, Jian ^b   Li, Bao Sheng ^a   Li, Hong Sheng ^a,b   Wang, Zhong Tang ^a   Yi, Yan ^a   Sun, Hong Fu ^a   Wang, Dong Qing ^a  

^a Shandong's Key Laboratory of Radition Oncology   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

18F FDG PET CT; Non small cell lung cancer; Radiotherapy; Shrinking field radiation

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; FEASIBILITY STUDY; FEMALE; GAMMA RADIATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PROGNOSIS; RADIATION DOSE; RADIOGRAPHY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; STANDARD;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA RAYS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84864924125     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.319     Document Type: Article

References (25)

1. Belderbos JS, Heemsbergen WD, De Jaeger K, et al (2006). Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 66, 126-34.
2. Blackstock AW, Ho C, Butler J, et al (2006). Phase Ia/Ib chemoradiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol, 1, 434-40.
3. Bradley J, Graham MV, Winter K, et al (2005). Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys, 61, 318-28.
4. Britton KR, Starkschall G, Tucker SL, et al (2007). Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys, 68, 1036-46.
5. Curran WJ, Scott CB, Langer CJ, et al (2003). Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410. Proc Am Soc Clin Oncol, 22, 621a (abstract 2499).
6. Eschmann SM, Friedel G, Paulsen F, et al (2007). Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage lll non-small cell lung cancer. Lung cancer, 55, 165-71.
7. Fox J, Ford E, Redmond K, et al (2009). Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 74, 341-8.
8. Gillham C, Zips D, Pönisch F, et al (2008). Additional PET/ CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol, 88, 335-41.
9. Gilman MD, Aquino SL (2005). State-of-the-art FDG-PET imaging of lung cancer. Semin Roentgenol, 40, 143-53.
10. Guckenberger M, Wilbert J, Richter A, et al (2011). Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys, 79, 901-8.
11. Hong R, Halama J, Bova D, et al (2007). Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys, 67, 720-6.
12. Kim TH, Cho KH, Pyo HR, et al (2005). Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 62, 995-1002.
13. Kim TY, Yang SH, Lee SH, et al (2002). A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol, 25, 238-43.
14. Kim YS, Yoon SM, Choi EK, et al (2005). Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys, 62, 76-81.
15. Kong FM, Ten Haken RK, Schipper MJ, et al (2005). High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys, 63, 324-33.
16. Kupelian PA, Ramsey C, Meeks SL, et al (2005). Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys, 63, 1024-8.
17. Li BS, Gong HY, Huang W, et al (2011). Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer. Am J Clin Oncol [Epub ahead of print].
18. MacManus M, Nestle U, Rosenzweig KE, et al (2009). Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol, 91, 85-94.
19. Nestle U, Kremp S, Grosu AL (2006). Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol, 81, 209-25.
20. Nestle U, Walter K, Schmidt S, et al (1999). 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys, 44, 593-7.
21. Rengan R, Rosenzweig KE, Venkatraman E, et al (2004). Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 60, 741-7.
22. Seppenwoolde Y, Muller SH, Theuws JC, et al (2000). Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 47, 681-90.
23. van Baardwijk A, Bosmans G, Boersma L, et al (2007). PETCT- based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys, 68, 771-8.
24. Willner J, Baier K, Caragiani E, et al (2002). Dose, volume, and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 52, 382-9.
25. Woodford C, Yartsev S, Dar AR, et al (2007). Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys, 69, 1316-22.